The Medical Advisor

OneDayMD Evidence Review Original publication: 2025   |   Major revisions: January, March, May and August 2026   |   Article type: Narrative evidence review / translational oncology update Abstract Cancer treatment is increasingly moving from a one-size-fits-all model toward biologically stratified combination therapy. Modern oncology can now target specific molecular alterations, activate antitumor immunity, manipulate cellular metabolism and, potentially, modify the gut microbiome. This review integrates four related areas of research: targeted therapy, immunotherapy, metabolic oncology and drug repurposing , with particular attention to the emerging role of Akkermansia and the gut microbiome. Targeted therapies provide the clearest example of precision oncology. In EGFR-mutated non-small-cell lung cancer (NSCLC), osimertinib (Tagrisso) is an established EGFR tyrosine-kinase inhibitor for appropriately selected patients. FDA labeling includes fi...

Abstract Background: Lung cancer, particularly advanced or metastatic non–small cell lung cancer (NSCLC) and small-cell lung cancer (SCLC), remains a leading cause of cancer mortality worldwide. Conventional therapies such as targeted agents, immunotherapy, and chemotherapy offer survival benefits but often yield limited results in treatment-resistant or late-stage disease. Repurposing widely available antiparasitic drugs — fenbendazole , ivermectin , and mebendazole — has garnered attention in integrative oncology communities due to reported anticancer effects in preclinical studies and emerging anecdotal clinical observations. Objective: To summarize a compilation of real-world case reports describing the use of fenbendazole, ivermectin, and mebendazole in lung cancer patients, highlighting reported clinical outcomes and therapeutic contexts. Methods: This review synthesizes case narratives and outcome descriptions publicly shared through online platforms, including clinicians...